Influenza_High-risk and special groups
Some individuals are at increased risk of complications from influenza disease, and may be eligible to receive a funded influenza vaccine. This factsheet identifies those at higher risk of severe outcomes from influenza and who would benefit from vaccination.
Overview
Of those hospitalised for Severe Acute Respiratory Illness (SARI) in Auckland in 2023, influenza-associated hospitalisation rates were higher in young children (0–4years) and the elderly (≥ 65 years) compared to other age groups, and also higher in Pacific Peoples and Māori ethnic groups compared to other ethnic groups. Influenza can lead to serious complications, such as heart or lung conditions, particularly within these high-risk groups.
References
1. Xie Y, Choi T, Al-Aly Z. Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study. The Lancet Infectious Diseases. 2024;24(3):239-55.
2. WHO National Influenza Centre HIT. Recommendation for seasonal influenza vaccine composition for New Zealand for 2026. Wellington: PHF Science/New Zealand Institute for Public Health and Forensic Science; 2025.
3. Heidecker B, Libby P, Vassiliou VS, Roubille F, Vardeny O, Hassager C, et al. Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement: With the contribution of the European Association of Preventive Cardiology (EAPC), the Association for Acute CardioVascular Care (ACVC), and the Heart Failure Association (HFA) of the ESC. European heart journal. 2025;46(36):3518-31.
4. Behrouzi B, Bhatt DL, Cannon CP, Vardeny O, Lee DS, Solomon SD, Udell JA. Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis. JAMA Network Open. 2022;5(4):e228873-e.
5. Fröbert O, Götberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, et al. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. 2021;144(18):1476-84.
6. James S, Haight RC, Hanna C, Furton L. Adults with Trisomy 21 Have Differential Antibody Responses to Influenza A. Vaccines. 2022;10(7):1145.
7. Wiggins KB, Smith MA, Schultz-Cherry S. The Nature of Immune Responses to Influenza Vaccination in High-Risk Populations. Viruses. 2021;13(6).
8. Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;6(6):CD002733.
9. Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Advances in chronic kidney disease. 2006;13(3):199-204.
10. Gilbertson DT, Unruh M, McBean AM, Kausz AT, Snyder JJ, Collins AJ. Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney international. 2003;63(2):738-43.
11. Stolley Z. The Connection between Influenza Vaccination and Dialysis Risk in Hypertensive Kidney Disease Patients. J Hypertens. 2024;13(485).
12. Stroffolini T, Stroffolini G. Vaccination in Patients with Liver Cirrhosis: A Neglected Topic. Vaccines. 2024;12(7):715.
13. Härmälä S, Parisinos CA, Shallcross L, O'Brien A, Hayward A. Effectiveness of influenza vaccines in adults with chronic liver disease: a systematic review and meta-analysis. BMJ open. 2019;9(9):e031070.
14. Horswell R, Chu S, Stone AE, Fort D, Uwaifo G, Fonseca VA, Norton EB. Risk of healthcare visits from influenza in subjects with diabetes and impacts of early vaccination. BMJ open diabetes research & care. 2024;12(4).
15. Remschmidt C, Wichmann O, Harder T. Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC medicine. 2015;13:53.
